BioCentury | Oct 5, 2019

Seeking bright spots in 4Q19 amid continued underperformance

Biotech watchers are hoping a busy fourth quarter of data readouts, regulatory actions and IPOs will provide some bright spots to counteract the sector’s continued overall underperformance, which is not expected to improve in 2020....
BC Extra | May 8, 2019
Financial News

CRO Viva raises $193.9 million in Hong Kong IPO

Viva will begin trading Thursday after raising HK$1.5 billion (US$193.9 million) early Wednesday in an IPO that values the drug discovery services company at HK$6.6 billion (US$843.1 million). Viva Biotech Holdings (HKSE:1873) sold 345 million...
BC Extra | May 8, 2019
Company News

Why dwarfism start-up Therachon picked Pfizer takeout over IPO

Rather than file for an IPO as it had been planning to do, Therachon has elected to take a buyout offer from Pfizer, handing the pharma a clinical program to treat achondroplasia. Pfizer will pay...
BC Extra | Mar 21, 2018
Company News

Weather delay for achondroplasia meeting

FDA postponed until further notice the March 22 joint meeting of the Pediatric Advisory Committee (PAC) and Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) due to inclement weather. The committees are slated to discuss drug...
BioCentury | May 12, 2017

Vertical vision

Shire plc ’s deal with Parion Sciences Inc. is a step toward building vertically in ophthalmics, much like it has done in hereditary angioedema and hemophilia. On May 1, Shire gained exclusive, worldwide rights to...
BC Innovations | Apr 6, 2017
Targets & Mechanisms

Competing for growth

With little in the clinical pipeline for achondroplasia beyond BioMarin Pharmaceutical Inc. ’s late-stage vosoritide, startups Therachon AG and BioClin Therapeutics Inc. are rethinking how to tackle the disease. By targeting FGFR3 directly, the two...
BC Week In Review | Dec 14, 2016
Clinical News

Vosoritide: Ph III started

BioMarin began a double-blind, placebo-controlled, international Phase III trial to evaluate daily vosoritide for 52 weeks in about 110 patients ages 5-14. Patients who complete the trial may be eligible to enroll in an open-label...
BC Extra | Apr 21, 2016
Clinical News

BioMarin updates plans for three late-stage programs

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) gave R&D updates on three late-stage programs: achondroplasia therapy vosoritide ( BMN 111 ), phenylketonuria (PKU) treatment pegvaliase ( BMN 165 ), and cerliponase alfa ( BMN 190 ) to treat late-infantile neuronal ceroid lipofuscinosis...
BC Week In Review | Mar 14, 2016
Company News

Chugai, BioMarin deal

Chugai granted BioMarin U.S. and Japanese rights to Chugai’s C-type natriuretic peptide ( CNP ; NPPC ) patent, which covers BioMarin’s achondroplasia candidate vosoritide . The analog of CNP is in Phase II testing to treat children with...
BioCentury | Jan 11, 2016

Sowing season

Stephen Hansen, Associate Editor   BUYSIDE VIEW XXIV While the biotech sector's three-year rocket ride isn't likely to continue in 2016, fund managers are still anticipating a slew of high-profile milestones in the New Year....
Items per page:
1 - 10 of 36